12.4 Neonatal Hyperbilirubinemia & Phototherapy

Neonatal Hyperbilirubinemia: Metabolism, Diagnosis & Phototherapy

Jaundice affects approximately 60% of term and 80% of preterm infants. While predominantly benign, severe unconjugated hyperbilirubinemia can cross the blood-brain barrier, precipitating acute bilirubin encephalopathy and irreversible neurologic damage (kernicterus).

Bilirubin Metabolism Overview

1. Production: Senescent erythrocytes are degraded by reticuloendothelial macrophages, converting heme into unconjugated (indirect) bilirubin. Neonates produce two to three times more bilirubin than adults (8 to 10 mg/kg/day) due to higher hematocrit (50%–60%) and shorter erythrocyte lifespan (70 to 90 days in neonates vs. 120 days in adults).
2. Transport: Unconjugated bilirubin is lipophilic, water-insoluble, and binds tightly to serum albumin for transport to the liver.
3. Hepatic Conjugation: In hepatocytes, the enzyme uridine diphosphate glucuronosyltransferase (UGT1A1) catalyzes the conjugation of indirect bilirubin with glucuronic acid to form water-soluble conjugated (direct) bilirubin, which is excreted into bile and the intestine.
4. Enterohepatic Circulation: The neonatal intestine possesses low bacterial flora to convert bilirubin to stercobilin, but high concentrations of mucosal beta-glucuronidase. This enzyme deconjugates intestinal bilirubin back into unconjugated bilirubin, which is reabsorbed through the gut mucosa into the portal bloodstream.

Clinical Progression & Visual Assessment Pitfalls

Jaundice progresses in a cephalocaudal direction: appearing first on the face and sclera (~5 mg/dL), progressing to the chest and upper abdomen (~8 to 10 mg/dL), lower abdomen and thighs (~12 to 15 mg/dL), and finally the palms and soles (>15 to 20 mg/dL).

• Visual estimation of bilirubin levels is notoriously subjective and unreliable, particularly in darkly pigmented infants.
• Clinical Standard: Every jaundiced infant must be objectively evaluated using a transcutaneous bilirubinometer (TcB) or a venous total serum bilirubin (TSB).

Physiologic vs. Pathologic Jaundice

Breastfeeding Jaundice vs. Breast Milk Jaundice

A frequent area of confusion on clinical exams is the differentiation between early intake-related jaundice and true breast milk jaundice:

Jaundice in the Breastfed Infant
├── Breastfeeding Jaundice (Suboptimal Intake) ──> Days 2 to 5  ──> Dehydration, weight loss, delayed stooling ──> Optimize feeds
└── Breast Milk Jaundice (Late-Onset Benign)   ──> Days 5 to 14 ──> Thriving infant, normal gain, lasts weeks ──> Continue nursing

• Breastfeeding Jaundice (Suboptimal Intake Jaundice / Early-Onset):
  • Timing: Manifests in the first 2 to 5 days of life.
  • Pathophysiology: Inadequate caloric and fluid intake due to delayed lactogenesis, poor latch, or infrequent feedings leads to mild dehydration, delayed stooling, and slow meconium transit, which drastically increases the enterohepatic reabsorption of unconjugated bilirubin.
  • Clinical Signs: Weight loss >8% to 10%, decreased wet diapers (<3/day), delayed passage of meconium, lethargy, concentrated uric acid "brick dust" crystals in urine.
  • Midwifery Management: Optimize breastfeeding frequency (8 to 12 feedings per 24 hours), evaluate latch and milk transfer with a lactation consultant, and supplement with expressed breast milk, donor milk, or formula if dehydration, excessive weight loss, or high bilirubin levels persist. Breastfeeding should NOT be discontinued.
• Breast Milk Jaundice (Late-Onset):
  • Timing: Onset occurs in late week 1 (days 5 to 7), peaks during weeks 2 to 3, and gradually resolves over 3 to 12 weeks.
  • Pathophysiology: Substances naturally present in mature maternal breast milk (e.g., beta-glucuronidase, non-esterified free fatty acids, and epidermal growth factor) inhibit hepatic UGT1A1 conjugation or enhance intestinal deconjugation.
  • Clinical Signs: The infant is completely healthy, alert, thriving, gaining weight vigorously, voiding normally, and passing soft yellow seedy stools.
  • Midwifery Management: Reassurance. Phototherapy is initiated only if TSB exceeds AAP risk thresholds. Breastfeeding should NOT be interrupted; temporary cessation is unnecessary and disrupts the lactation relationship.

Phototherapy & Exchange Transfusion Guidelines

• The AAP Hour-Specific Nomogram (Bhutani Nomogram): Guides clinical intervention by plotting total serum bilirubin against infant post-natal age in hours, stratified by gestational age (≥38 weeks vs. 35–37 weeks) and the presence of neurotoxicity risk factors (e.g., positive DAT/Coombs hemolysis, G6PD deficiency, sepsis, asphyxia, serum albumin <3.0 g/dL).
• Mechanism of Phototherapy: Narrow-band blue-green light (wavelength 460 to 490 nm) penetrates superficial skin capillaries. Photons hit unconjugated bilirubin molecules, driving a structural photoisomerization reaction that converts toxic, lipid-soluble 4Z,15Z-bilirubin into lumirubin. Lumirubin is a stable, water-soluble structural isomer that does NOT require hepatic glucuronide conjugation and is excreted directly into bile and urine.
• Midwifery Nursing Care During Phototherapy:
  1. Maximize exposed skin surface area (infant wears only a small diaper).
  2. Place opaque protective eye shields over the infant's eyes to prevent phototoxic retinal damage; remove shields during feedings to evaluate eyes and promote bonding.
  3. Maintain infant thermal neutrality under lights; monitor temperature closely.
  4. Ensure optimal enteral hydration to facilitate urinary and fecal lumirubin excretion.
  5. Turn off phototherapy lights when drawing blood for bilirubin levels to avoid photodegradation in the specimen tube.
  6. Bronze Baby Syndrome: An unusual, dark grayish-brown discoloration of the skin, serum, and urine occurring when phototherapy is inadvertently applied to infants with elevated direct (conjugated) hyperbilirubinemia (cholestatic jaundice), caused by photo-oxidation of retained copper porphyrins. Phototherapy is contraindicated in cholestasis.
• Exchange Transfusion & Acute Bilirubin Encephalopathy (ABE):
  • Reserved for severe hyperbilirubinemia where TSB reaches or exceeds exchange transfusion thresholds, or when the infant exhibits intermediate-to-advanced signs of Acute Bilirubin Encephalopathy (ABE):
    • Early Phase: Lethargy, poor feeding, mild hypotonia.
    • Intermediate Phase: Stupor, irritability, high-pitched shrill cry, hypertonia, retrocollis (neck arching backward), and opisthotonos (severe trunk arching backward).
    • Advanced Phase: Inconsolable crying, inability to feed, bicycling movements, apnea, intractable seizures, coma, and death.
  • Kernicterus (Chronic Bilirubin Encephalopathy): Permanent, irreversible neurodevelopmental damage caused by unconjugated bilirubin depositing in the basal ganglia (especially the globus pallidus), subthalamic nuclei, and auditory brainstem pathways. The classic tetrad of kernicterus includes:
    1. Choreoathetoid cerebral palsy (involuntary, uncoordinated movements)
    2. Sensorineural hearing loss / auditory neuropathy
    3. Upward gaze palsy (paralysis of upward conjugate ocular movement)
    4. Dental enamel dysplasia of primary deciduous teeth.